Cybin Inc.

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-12-06 pm EST			5-day change	1st Jan Change
10.80 ^USD	+1.50%		+4.05%	-30.68%

Nov. 18	Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	MT
Nov. 18	Cybin Inc. - Special Call

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Cybin Inc.

Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	Nov. 18	MT
Cybin Inc. - Special Call	Nov. 18
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder	Nov. 18	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 13	CI
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results	Nov. 13	CI
Cybin Inc. - Special Call	Oct. 08
Cybin Inc. Announces Executive Appointments	Oct. 01	CI
Cybin Inc.(NYSEAM:CYBN) added to S&P Global BMI Index	Sep. 22	CI
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones	Sep. 20	CI
Cybin Inc. - Shareholder/Analyst Call	Aug. 27
Cybin to Begin Phase 3 Trial of Treatment for Major Depressive Disorder This Summer	Aug. 13	MT
Cybin Inc. Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder	Aug. 13	CI
Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee	Aug. 13	CI
Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2024	Aug. 08	CI
Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 26	CI
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	Jun. 11	CI
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	May. 06	CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	Apr. 17	MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	Apr. 16	MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors	Mar. 18	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15	MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	Mar. 15	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	Mar. 15	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	Mar. 14	MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	Mar. 14	CI

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-12-11 - Water Tower Research Conference

More about the company